Superworth

Nexentis Technologies revenue NXTS

Sales by quarter and over the last twelve months, from 2019.

Last 12 months, to Sep 30, 2025
n/m
a quarter missing
Latest quarter, Q3 FY25
$2K
−78% on a year earlier
Fiscal year 2022
$394K
−10% on the year before

Nexentis Technologies' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q3 FY25, it was $2K, down 78% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2022$394K−10%
FY2021$438.1K+89%
FY2020$232.3K+32%
FY2019$175.8Kn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY25$2K−78%n/a
Q2 FY25$0−100%n/a
Q1 FY25$66K+51%n/a
Q3 FY24$9.1Kn/an/a
Q2 FY24$16.5K−55%n/a
Q1 FY24$43.8K−64%n/a
Q3 FY23$0−100%$381.7K
Q2 FY23$36.6K+18%$432.9K
Q1 FY23$121K+38%$427.4K
Q4 FY22$224.1K+18%$394K
Q3 FY22$51.2K−28%$359.2K
Q2 FY22$31.1K−43%$379.4K

Against its peers

Companies in Drug Manufacturers - General nearest Nexentis Technologies' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
NXTSNexentis Technologiesn/m
LABTLakewood-Amedex Biotherapeuticsn/m
JAGXJaguar Health$27.8M+136% a year
VBIOValion Bion/m
DCOYDecoy Therapeuticsn/m
SBFMSunshine Biopharma$35.3M−3% a year
ARTLArtelo Biosciencesn/m
LNAILunai Bioworksn/m
GNPXGenprexn/m
GOVXGeoVax Labs$0−100% a year
ONCOOnconetixn/m
Peer median$27.8M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Nexentis Technologies

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.